SAWAI GROUP HOLDINGS Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter saw higher revenue but lower earnings, with cost increases and inventory accumulation affecting profitability and cash flow as the key points. Revenue increased to ¥516.2B (+4.3% YoY), but Operating Income declined significantly to ¥49.5B (-29.0%) and Net Income to ¥24.3B (-50.3%). In addition to the decline in gross margin (29.2%, approximately -100bp YoY), increases in selling, general and administrative expenses (+16.4%) and research and development expenses (+22.9%) exceeded revenue growth, causing negative operating leverage and representing the primary factors behind the decline.

Factors Affecting Performance

【Revenue】Revenue was ¥516.2B (+4.3% YoY). By therapeutic category, cardiovascular drugs, other metabolic drugs, and central nervous system drugs contributed to revenue growth, while antibiotic preparations (2,535→2,088 million yen) and respiratory drugs (1,925→1,457 million yen) declined. The main contributor to revenue growth was other metabolic drugs (+1,938 million yen), with changes in the product mix reflected in the revenue composition.

【Profit and Loss】Operating Income was ¥49.5B (-29.0% YoY), Profit Before Tax was ¥44.5B (-34.7%), and Net Income was ¥24.3B (-50.3%). Cost of sales increased by +7.2%, deteriorating the gross margin, while increases in selling, general and administrative expenses and research and development expenses pressured earnings. Finance costs also increased to ¥5.6B (¥3.1B in the previous year), weighing on Profit Before Tax. In addition, a loss of ¥4.3B from discontinued operations further reduced Net Income. Overall, the Company posted higher revenue but lower earnings.

Segment Analysis

The business consists of a single segment, “Manufacturing and sales of pharmaceuticals and related products,” and operating income and loss by business are not disclosed. By therapeutic category, revenue from cardiovascular drugs increased to ¥117.1B (¥115.5B in the previous year), other metabolic drugs to ¥77.3B (¥57.9B in the previous year, +33.5%), and central nervous system drugs to ¥74.5B (¥69.9B in the previous year). Meanwhile, antibiotic preparations (-17.6%) and respiratory drugs (-24.3%) declined, resulting in a composition in which growth and contraction areas coexist.

Key Financial Indicators

【Profitability】The Operating Income margin was 9.6%, down from approximately 13.1% in the previous year, while the Net Income margin also contracted significantly to 4.7% from approximately 9.9% in the previous year. The gross margin was 29.2%, down from the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was -¥4.3B, below Net Income of ¥24.3B, resulting in a negative OCF/Net Income ratio. The primary factor was a ¥79.7B quarterly increase in inventories, indicating a lengthening inventory turnover period.【Investment Efficiency】ROE was 1.4%; as Net Income contracted while assets expanded, capital efficiency remained low.【Financial Soundness】The Equity Ratio declined slightly to 48.1% (49.6% in the previous year) but remained at a conservative level. Short-term borrowings rose sharply to ¥398.2B (¥146.8B in the previous year), indicating that investment and inventory funding is being supplemented through short-term financing.

Cash Flow Analysis

Operating Cash Flow (OCF) was -¥4.3B, an improvement from -¥134.1B in the previous year, but cash conversion has not progressed relative to Net Income of ¥24.3B. The primary factor was the ¥79.7B increase in inventories, with deterioration in working capital offsetting cash generation from operating activities. Investing Cash Flow was -¥127.1B, of which ¥105.8B comprised capital expenditures, indicating a more aggressive investment stance than in the previous year (-¥24.0B). As a result, Free Cash Flow was -¥131.3B, with funding requirements covered by Financing Cash Flow of +¥102.0B, particularly a net increase in short-term borrowings of ¥156.5B. Cash and cash equivalents declined to ¥260.6B, highlighting an increasing dependence on short-term debt in the funding structure.

Earnings Quality

Current-period Net Income of ¥24.3B includes a ¥4.3B loss from discontinued operations, which can be distinguished as a temporary factor. Profit from continuing operations alone was ¥28.6B, and the decline in earnings would be somewhat smaller on this basis. Finance costs increased to ¥5.6B, with non-operating costs weighing on Profit Before Tax. Comprehensive income was ¥23.2B, remaining approximately at the same level as Net Income of ¥24.3B; the divergence attributable to other comprehensive income (a -¥1.1B change in financial assets measured at fair value) was limited. Meanwhile, the fact that OCF was below Net Income warrants attention from an accrual perspective, as the gap between accounting earnings and cash generation resulting from inventory accumulation is a key issue in assessing earnings quality.

Earnings Forecast and Guidance

Against the full-year Company plan, Revenue was ¥208.4B compared with ¥516.2B in the current quarter, representing progress of 24.8% and generally consistent with seasonality (Q1 benchmark: 25%). Meanwhile, Operating Income was 18.2% of the full-year target of ¥272.0B, and Net Income was 13.1% of the full-year target of ¥186.0B (attributable to owners of the parent), indicating that earnings progress is lagging revenue progress in both cases. The full-year plan forecasts growth of +71.1% in Operating Income and +78.2% in Net Income, and appears to incorporate an assumption that the Q1 deterioration in gross margin and increase in expenses will recover toward the second half of the fiscal year. No revisions to the earnings forecast had been made as of the current quarter.

Shareholder Returns

Dividend payments during the current quarter were ¥32.3B (¥31.2B in the previous year), and the full-year forecast dividend per share is 56 yen. Using the full-year forecast Net Income of ¥186.0B (attributable to owners of the parent) as the denominator, the Payout Ratio calculated from the estimated total dividend amount (approximately 115.5 million issued shares × 56 yen = approximately ¥64.7B) is approximately 34.8%. Free Cash Flow for the current quarter was negative at -¥131.3B, confirming that dividends are currently being supported not by cash generated from operating activities but by borrowings and other financing sources.

Risk Factors

1. Working capital risk associated with inventory accumulation: Inventories increased to ¥1,255.8B (¥1,176.1B at the end of the previous fiscal year, +¥79.7B), putting pressure on OCF. If elevated inventory levels persist, the impact on cash-generation capacity may continue over the longer term.

2. Refinancing risk arising from dependence on short-term funding: Short-term borrowings increased sharply to ¥398.2B (+171.4% from ¥146.8B at the end of the previous fiscal year). The ratio to cash and cash equivalents of ¥260.6B was approximately 0.65x, indicating an increased dependence on short-term debt.

3. Declining profitability: The Operating Income margin was 9.6% (down from approximately 13.1% in the previous year), and the Net Income margin was 4.7% (down from approximately 9.9% in the previous year). Growth in selling, general and administrative expenses and research and development expenses (+16.4% and +22.9%, respectively) exceeded revenue growth (+4.3%), making the absorption of cost increases a key challenge.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

The Company’s profitability metrics are below the industry median, with its Operating Income margin particularly ranking in the lower tier of the industry.

Growth and Capital Efficiency

Revenue growth also fell below the industry median, indicating that top-line growth is relatively moderate within the industry.

※Source: Compiled by the Company

Key Points in the Earnings Results

1. Although the top line achieved revenue growth of 4.3%, the decline in gross margin and growth in selling, general and administrative expenses and research and development expenses (+16.4% and +22.9%, respectively) exceeded revenue growth, causing the Operating Income margin to decline to 9.6%. The impact of changes in the cost structure on earnings quality warrants close monitoring.

2. Inventories increased by ¥79.7B during the quarter, while OCF remained at -¥4.3B. A gap has emerged between earnings and cash generation, making inventory trends a structural issue affecting the quality of cash flow.

3. Progress against the full-year plan was 24.8% for Revenue, compared with 18.2% for Operating Income and 13.1% for Net Income, indicating a lag in earnings progress. The full-year plan anticipates significant earnings growth, making the presence or absence of a recovery in profitability toward the second half of the fiscal year an important point to monitor when evaluating actual performance.

Theoretical Share Price (Reference Value)

Sensitivity: 1,586 yen–1,679 yen at ±1% in the cost of equity, and 1,629 yen–1,635 yen at ±0.1 in ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / These are mechanically calculated values based solely on publicly disclosed data and do not constitute a forecast of the market share price or a recommendation of any specific investment action, nor do they predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a weak earnings quarter despite continued top-line growth, with margin compression, a discontinued-operation loss, and substantial inventory-led cash absorption. Revenue rose 4.3% YoY to ¥51.62bn. Operating income fell 29.0% YoY to ¥4.95bn, reducing the operating margin to 9.6% from 14.1% a year earlier, a 450bp contraction. Gross profit declined 2.3% YoY to ¥15.08bn even as revenue expanded, and gross margin fell 200bp to 29.2%. SG&A increased 16.4% YoY to ¥7.02bn, outpacing sales growth by 12.1 percentage points. R&D expenditure increased 22.9% YoY to ¥2.97bn, lifting R&D intensity by approximately 90bp to 5.8% of revenue. These increases, alongside a ¥0.53bn impairment loss and higher finance costs, pressured operating and pre-tax profit. Finance costs rose to ¥0.56bn from ¥0.31bn, while finance income declined to ¥0.05bn from ¥0.13bn. Net income declined 50.3% YoY to ¥2.43bn, with a ¥0.43bn loss from discontinued operations accounting for a meaningful part of the decline. Basic EPS therefore fell to ¥21.04 from ¥42.36. Operating cash flow was negative ¥0.43bn despite positive net income, principally because inventory increased ¥7.97bn. Free cash flow was negative ¥13.13bn after elevated capital expenditure and intangible-asset investment. The company funded the quarterly cash deficit partly through a ¥15.65bn net increase in short-term borrowings. The balance sheet retains a 48.1% equity ratio and a 2.00x current ratio, but the liquidity mix is weakened by inventory representing 61.6% of current assets and by a sharp increase in short-term debt. FY2027 guidance was maintained, but Q1 progress was only 18.2% for operating income and 13.1% for net income versus the standard 25% quarterly pace. The investment debate is therefore centered on whether the inventory build, investment spending, R&D expansion, and discontinued-operation loss are temporary factors that can reverse through the remainder of the year. Execution against profitability recovery and conversion of inventories into operating cash flow are the principal near-term determinants of earnings quality.

Profitability Analysis

Annualized DuPont ROE is 5.5%, comprising a 4.7% net profit margin, 0.560x annualized asset turnover, and 2.08x financial leverage. The net margin is the main constraint on shareholder returns: the 4.7% margin is below the 5% threshold generally associated with a satisfactory pharmaceutical profitability profile and compares with a 9.9% margin in the prior-year quarter. Financial leverage supports the reported ROE but does not offset the weaker profit conversion. Operating margin fell by 450bp YoY to 9.6%, remaining within the 8-15% benchmark range but moving materially lower within that range. Gross margin contracted by 200bp to 29.2%, indicating that cost of sales grew faster than revenue. SG&A rose 16.4% YoY and R&D rose 22.9% YoY, both materially faster than the 4.3% revenue increase, demonstrating negative operating leverage in Q1. The approximately ¥3.62bn reduction in gross profit, ¥0.99bn rise in SG&A, ¥0.55bn increase in R&D, and ¥0.12bn deterioration in other income and expenses explain the ¥2.03bn operating-profit reduction. R&D intensity was 5.8%, which is below the 15-20% innovator-pharma benchmark but is consistent with the company's generic-drug-centered model, where formulation development, manufacturing capability, and product-launch execution are more relevant than discovery-stage pipeline investment. The interest burden was 0.897, reflecting a moderate drag from net finance costs, while the tax burden of 0.546 was depressed by the loss in discontinued operations. The effective tax rate on reported pre-tax income was 35.6%. The quality alert citing a tax burden based on a 45% effective tax rate is not supported by the disclosed income-tax expense and pre-tax profit; nevertheless, the 0.546 tax-burden ratio shows that profit after tax was materially lower than pre-tax profit in this quarter.

Growth Assessment

Revenue growth of 4.3% was supported principally by other metabolic drugs, which increased 33.5% YoY to ¥7.73bn, and central nervous system drugs, which increased 6.5% to ¥7.45bn. Oncology products also increased 19.0% to ¥1.94bn, while urogenital products rose 17.3% to ¥1.58bn. Cardiovascular products, the largest therapeutic category at ¥11.71bn, grew a modest 1.4%, demonstrating a stable but mature core revenue base. Growth was offset in part by respiratory products, down 24.3% to ¥1.46bn, antibiotics, down 17.6% to ¥2.09bn, and digestive products, down 3.5% to ¥5.37bn. The therapeutic-area mix indicates that growth is coming from a subset of product categories rather than being broad based. The key issue is that revenue growth did not translate into earnings growth because gross-margin pressure and operating-cost growth exceeded the top-line benefit. Full-year guidance calls for revenue of ¥208.40bn, operating income of ¥27.20bn, and net income attributable to owners of ¥18.60bn. Q1 revenue progress was 24.8%, broadly in line with the standard 25% pace. Operating-income progress was 18.2%, 6.8 percentage points below the standard pace, while net-income progress was 13.1%, 11.9 percentage points below pace and therefore requires a material acceleration over the remaining three quarters. The maintained forecast implies management expects the Q1 margin and discontinued-operation effects not to persist at the same intensity. The absence of a forecast revision preserves the full-year target but raises the importance of subsequent-quarter evidence on cost of sales, R&D and SG&A discipline, and inventory normalization.

Financial Health

Liquidity is adequate on a headline current-ratio basis: current assets of ¥203.70bn covered current liabilities of ¥101.66bn, equivalent to a 2.00x current ratio. However, liquidity is materially less robust on a quick basis because inventories totaled ¥125.58bn; the calculated quick ratio was approximately 0.77x. Cash and cash equivalents were ¥26.06bn, equal to 0.65x short-term loans of ¥39.82bn. Accordingly, the quality alert describing cash-to-short-term-debt as below 0.5x is not supported by the disclosed amounts, but cash alone does not fully cover short-term borrowings and refinancing access remains important. Total bonds and borrowings were ¥118.97bn, consisting of ¥39.82bn of short-term loans and ¥79.15bn of noncurrent borrowings. Total borrowings represented approximately 0.67x equity and 33.5% of total borrowings were short term. This does not support the quality alert that the short-term debt ratio is 100%; the disclosed debt structure includes substantial noncurrent borrowings. Nevertheless, short-term loans increased ¥25.15bn, or 171.4%, from the prior fiscal year-end, while noncurrent borrowings declined ¥11.20bn, indicating a meaningful shift toward shorter-term funding during the quarter. This creates a maturity-management risk if operating cash generation does not improve. The equity ratio declined from 49.6% at the prior year-end to 48.1%, but remains reasonable for a manufacturing business with a large fixed-asset base. Debt/capital of 18.3% is conservative relative to the 40% investment-grade benchmark. Operating income covered finance costs by approximately 8.8x, suggesting that the current interest burden remains serviceable. Property, plant and equipment accounted for 32.8% of total assets, while intangible assets accounted for 8.1%; the latter is below the 20% concentration benchmark.

Notable B/S Changes

Short-term loans: +¥25.15bn (+171.4%) from the prior fiscal year-end to ¥39.82bn - material increase in short-term funding, partly supporting the Q1 operating and investment cash deficit; refinancing and maturity management warrant close monitoring. Noncurrent bonds and borrowings: -¥11.20bn (-12.4%) from the prior fiscal year-end to ¥79.15bn - alongside the rise in short-term loans, this indicates a meaningful shift in the debt maturity mix toward shorter-term funding. Inventories: +¥7.97bn (+6.8%) from the prior fiscal year-end to ¥125.58bn - the increase consumed operating cash flow and increased inventory intensity to 34.0% of total assets; the commercial conversion of this inventory is a key near-term issue.

Cash Flow Quality

Cash-flow quality was weak in Q1. Operating cash flow was negative ¥0.43bn compared with net income of ¥2.43bn, producing an OCF/net-income ratio of negative 0.18x and validating the earnings-quality alert. The immediate root cause was a ¥7.97bn inventory increase, substantially greater than the ¥3.48bn inventory build in the prior-year quarter. Other working-capital changes also consumed ¥3.48bn. The inventory increase lifted closing inventories to ¥125.58bn, equal to 34.0% of total assets and 61.6% of current assets. The reported inventory-days alert of 314 days is materially above the stated 60-90 day reference levels; for a generic-drug manufacturer, safety-stock and supply-assurance requirements can raise working-capital needs, but this level of capital tied up in inventory materially reduces cash conversion and should be monitored closely. The impact is heightened because revenue grew only 4.3%, meaning the inventory build substantially exceeded the pace of sales growth. Receivables decreased by ¥1.37bn and payables increased by ¥1.18bn, partly mitigating the inventory outflow, but not enough to restore positive operating cash flow. Cash generation was also affected by ¥1.34bn of tax payments and ¥0.49bn of interest payments. Capital expenditure was ¥10.58bn and intangible-asset purchases were ¥2.02bn, resulting in reported free cash flow of negative ¥13.13bn. Capex was approximately 2.43x depreciation and amortization of ¥4.35bn, showing an investment-heavy quarter rather than underinvestment. The negative operating cash flow, investment spending, and ¥3.23bn dividend payment were financed in part by the ¥15.65bn increase in short-term borrowings. This funding pattern is not sustainable indefinitely without improved operating cash conversion, but it may normalize if the inventory build supports future generic launches or supply commitments and is converted into sales.

Dividend Sustainability

The full-year dividend forecast is ¥56.00 per share, unchanged from the company forecast. Against forecast FY2027 EPS of ¥161.08, the implied dividend payout ratio is 34.8%, which is comfortably below the 60% sustainability benchmark. The quarterly dividend payment of ¥3.23bn equated to approximately ¥28 per share. On Q1 reported EPS of ¥21.04, the quarterly dividend exceeded quarterly earnings, but quarterly payout comparisons are not decisive because earnings are seasonal and the company has maintained a full-year earnings forecast. The more immediate constraint is cash flow: reported free cash flow was negative ¥13.13bn in Q1, and operating cash flow was also negative. Thus, the dividend was not covered by internally generated Q1 cash after investment spending and was effectively supported by balance-sheet liquidity and short-term borrowing. Retained earnings remained substantial at ¥160.79bn, and the forecast payout ratio provides accounting earnings capacity for the annual dividend. Dividend sustainability therefore depends less on the stated payout ratio and more on normalization of inventory-related working-capital outflows and moderation of investment cash requirements during the remaining quarters. No share buyback was disclosed in the period, so no total return ratio is calculated.

Risk Assessment

Business risks include Generic-drug price competition and reimbursement-policy pressure could prolong the 200bp gross-margin decline, particularly if manufacturing, procurement, or distribution costs cannot be recovered through pricing., Revenue growth is concentrated in selected therapeutic categories, notably other metabolic and central nervous system products, while respiratory, antibiotics, and digestive products declined; sustained weakness in these categories could limit the sales base supporting fixed manufacturing costs., The ¥7.97bn inventory build creates execution risk: if demand, product mix, regulatory timing, or supply-chain assumptions do not develop as planned, cash conversion and inventory valuation could deteriorate., The ¥0.53bn impairment loss and ¥0.43bn discontinued-operation loss indicate non-core asset and portfolio-execution risk, with further restructuring or disposal costs potentially affecting reported earnings..

Financial risks include Short-term loans increased 171.4% to ¥39.82bn, and negative operating cash flow required additional short-term funding; continued cash deficits would increase refinancing dependence., Cash of ¥26.06bn covers only 65% of short-term loans, while the quick ratio is approximately 0.77x after excluding inventories., Finance costs increased 82.5% YoY to ¥0.56bn; further borrowing or higher interest rates would reduce interest coverage and pre-tax earnings., Negative free cash flow of ¥13.13bn reduces flexibility for dividends, debt reduction, and further manufacturing investment if it persists..

Key concerns include Highest priority: conversion of the inventory build into revenue and operating cash flow. The disclosed 314 inventory days and negative 0.18x OCF/net-income ratio make this the clearest earnings-quality concern., High priority: recovery of operating margin toward the level needed to support unchanged FY2027 guidance, given Q1 operating-income progress of only 18.2%., High priority: short-term funding management. Although disclosed data do not support the alert's 100% short-term debt ratio or sub-0.5x cash/debt ratio, the increase in short-term loans is material and warrants monitoring., Moderate priority: discontinuation and impairment-related charges. These items reduced Q1 net income and can obscure underlying operating performance if recurring., The tax-burden alert should be interpreted cautiously: the disclosed effective tax rate is 35.6%, not 45%, but the 0.546 tax burden remains low because Q1 includes a loss from discontinued operations..

Investment Implications

Key takeaways include Revenue remains on plan at 24.8% of full-year guidance, but profitability and net-income progress lag the normal Q1 pace., The 450bp operating-margin decline reflects lower gross margin and expense growth materially ahead of revenue growth., Cash conversion is the central financial issue, as inventory growth drove negative operating cash flow despite positive earnings., The balance sheet remains adequately capitalized, but Q1 funding relied on sharply higher short-term borrowings., The maintained dividend forecast has a moderate 34.8% payout ratio on full-year forecast EPS, although Q1 free cash flow did not fund the distribution..

Metrics to watch include Gross margin and operating margin recovery from Q1 levels of 29.2% and 9.6%, respectively., Inventory balance, inventory days, and the pace of inventory-related operating cash flow., Operating cash flow relative to net income and free cash flow after capex and intangible investment., Short-term loans, cash-to-short-term-debt coverage, and the maturity mix of borrowings., Progress toward FY2027 operating-income guidance of ¥27.20bn and net-income guidance of ¥18.60bn., Expense growth in SG&A and R&D relative to revenue growth., Further impairment charges, discontinued-operation losses, or other portfolio-related non-recurring items..

Regarding relative positioning, The company combines a stable generic-drug revenue base, a solid 48.1% equity ratio, and a forecast dividend payout ratio below conventional sustainability thresholds. However, its Q1 profile is weaker than a high-quality defensive pharmaceutical earnings profile because revenue growth was not converted into operating profit or cash flow, inventory intensity is high, and short-term funding increased materially. Relative positioning over the next quarters will depend on whether manufacturing and inventory investment supports profitable sales growth rather than becoming a persistent drag on margins and cash conversion.